Faculty profile

Christopher Ma

ResearcherMedicineUniversity of Calgary

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses may be missing. Find their university profile.

Christopher Ma

Researcher

Medicine

Health Sciences

University of Calgary

Calgary, Alberta, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
233 publications in the last five years, latest in 2026.
Senior (last) author on 37 recent papers, a sign of leading a research group.
Principal investigator on 5 research grants (5 CIHR), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

322

Publications

849

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Crohn'S Disease Inflammatory Bowel Disease Cost-Utility Epidemiology Forecast Knowledge Mobilization Patient Partners Pharmacoepidemiology

Latest papers

COMPARATIVE REAL-WORLD EFFECTIVENESS OF BIOLOGIC THERAPIES FOR PREVENTING POSTOPERATIVE ENDOSCOPIC RECURRENCE OF CROHN'S DISEASE.
The American journal of gastroenterology · 2026 · senior author
Effectiveness of Risankizumab After Ustekinumab Failure in Crohn's Disease: A Multicenter Retrospective Cohort Study.
Gastroenterology · 2026 · senior author
Antibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies.
Drugs · 2026 · senior author

All 322 publications

Latest funding

Steatotic Liver Disease, Fibrosis and Inflammatory Bowel Disease: Uncovering the Triple Threat
CIHR · 2026 · Co-investigator
$1,005,976
Inflammatory Bowel Disease in 2035: A National Study of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC)
CIHR · 2024 · Principal investigator
$100,000
VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients with Cancer: A Randomized, Double-Blinded, Placebo-Controlled Trial
CIHR · 2024 · Nominated PI
$397,799

All 7 grants and awards

From the 150 most recent of 322 publications.

COMPARATIVE REAL-WORLD EFFECTIVENESS OF BIOLOGIC THERAPIES FOR PREVENTING POSTOPERATIVE ENDOSCOPIC RECURRENCE OF CROHN'S DISEASE.

Ahmed NS, Boparai R, Fida M, Wang C, Clarke AN, Hamidi N, Maclean AR, Buie WD, Silverberg MS, Kotze PG, Lu C, Novak KL, Seow CH, St-Pierre J, Kaplan GG, Panaccione R, Ma C

The American journal of gastroenterology2026Senior author

DOI: 10.14309/ajg.0000000000004213 PMID: 42754967

Effectiveness of Risankizumab After Ustekinumab Failure in Crohn's Disease: A Multicenter Retrospective Cohort Study.

Mehta-Dhand S, Hamidi N, Clarke AN, Hoentjen F, Panaccione R, Ma C, IBD Clinics of the University of Calgary and University of Alberta

Gastroenterology2026Senior author

DOI: 10.1053/j.gastro.2026.04.029 PMID: 42107795

Antibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies.

Faggiani I, Tuttle C, Danese S, Peyrin-Biroulet L, Jairath V, Sedano R, Dotan I, Panaccione R, Ma C

Drugs2026Senior author

DOI: 10.1007/s40265-026-02383-1 PMID: 42745024

Recommendations for the Evaluation and Management of Inflammatory Bowel Disease With Irritable Bowel Syndrome-Like Symptoms: A Joint Rome Foundation and International Organization for the Study of IBD (IOIBD) Consensus.

Ma C, Ford AC, Hashash JG, Barbara G, Bernstein CN, Brenner DM, Griffiths AM, Keefer L, Long MD, Nurko S, Singh P, Sands BE, Chang L

Gastroenterology2026First author

DOI: 10.1053/j.gastro.2026.04.008 PMID: 42066865

Inflammatory and Immune Pathways Driving Tumor Necrosis Factor Inhibitor Resistance in Ulcerative Colitis.

Fairweather M, Faggiani I, Ma C

Journal of inflammation research2026Senior author

DOI: 10.2147/jir.s546264 PMID: 42670519

The Incidence of Esophageal Food Impactions and Risk Factors for Recurrence in a Large, Community-Based Health Care System in Northern California.

Lam AY, Xie W, Naveed M, Song J, Billett NM, Bakr O, Oh A, Boparai ES, Stram DA, Ma C, Lee JK

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026

DOI: 10.1016/j.cgh.2026.08.012 PMID: 42637172

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.

Gupte D, Suthar NR, MacDonald JK, Le J, Colman RJ, Feagan BG, Cheng C, Hanzel J, Ma C, Jairath V, Crowley E

Paediatric drugs2026

DOI: 10.1007/s40272-026-00766-1 PMID: 42595931

Temporal trends in depression-related hospitalizations and suicide among patients with inflammatory bowel disease.

Markovinović A, Ma C, Shaheen AA, Coward S, Kaplan GG

Journal of the Canadian Association of Gastroenterology2026

DOI: 10.1093/jcag/gwag015 PMID: 42553753

Comparative Outcomes After Index Myocardial Infarction in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Nguyen B, Quon S, Ma C, Singh S

Journal of clinical gastroenterology2026

DOI: 10.1097/mcg.0000000000002372 PMID: 42044218

Incidence and prevalence of immune-mediated extraintestinal manifestations in pediatric inflammatory bowel disease: a systematic review and meta-analysis.

Colman RJ, Vuyyuru SK, Solitano V, MacDonald JK, Le J, Ricciuto A, Berard R, Mohammed JA, Ma C, Jairath V, Crowley E

Crohn's & colitis 3602026

DOI: 10.1093/crocol/otag024 PMID: 42027410

Steatotic Liver Disease, Fibrosis and Inflammatory Bowel Disease: Uncovering the Triple Threat

Co-investigatorCIHR2026Project Grant

Principal investigators: Sebastiani, Giada; Bessissow, Talat; Betel, Michael; Saeed, Sahar Z; Swain, Mark G; Williams, Astrid-Jane

Keywords: Biobank; Biological Sex; Diabetes; Inflammatory Bowel Disease; Liver Fibrosis; Obesity; Patient Reported Outcomes; Risk Score; Steatotic Liver Disease

$1,005,976

Inflammatory Bowel Disease in 2035: A National Study of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC)

Principal investigatorCIHR2024Project Grant - PA: Nutrition, Metabolism and Diabetes

Principal investigators: Kaplan, Gilaad G; Benchimol, Eric I; Leal, Jenine R; Lee, Kate; Ma, Christopher; Pena-Sanchez, Juan-Nicolas

Keywords: Cost-Utility; Crohn'S Disease; Epidemiology; Forecast; Inflammatory Bowel Disease; Knowledge Mobilization; Patient Partners; Pharmacoepidemiology; Ulcerative Colitis

$100,000

VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients with Cancer: A Randomized, Double-Blinded, Placebo-Controlled Trial

Nominated PICIHR2024Project Grant

Principal investigators: Ma, Christopher

Keywords: Adverse Events; Checkpoint Colitis; Colitis; Diarrhea; Immunotherapy; Placebo; Prevention; Randomized Controlled Trial

$397,799

Managing the Burden of Inflammatory Bowel Disease over the Next Decade: A National Study of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC)

Principal investigatorCIHR2024Project Grant

Principal investigators: Kaplan, Gilaad G; Benchimol, Eric I; Bernatsky, Sasha R; Leal, Jenine R; Lee, Kate; Ma, Christopher; Pena-Sanchez, Juan-Nicolas; Tandon, Parul

Keywords: Cost-Utility; Crohn'S Disease; Epidemiology; Forecast; Inflammatory Bowel Disease; Knowledge Mobilization; Patient Partners; Pharmacoepidemiology; Prevalence; Ulcerative Colitis

$650,252

PATHFINDER: A Pragmatic, Active Comparator, Parallel-Group, Randomized Trial to Evaluate the Optimal First-Line Treatment Strategy for Moderate to Severely Active Ileal Crohn's Disease

Nominated PICIHR2022Project Grant

Principal investigators: Ma, Christopher

Keywords: Biologic; Crohn'S Disease; Endoscopic Remission; Inflammatory Bowel Disease; Natural History; Pilot; Pragmatic; Probe; Randomized Clinical Trial

$244,800

IMAGINE (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects) SPOR Chronic Disease Network - Knowledge Mobilization & Implementation Science Phase 2

Principal investigatorCIHR2021SPOR Networks - Knowledge Mobilization and Implementation Science

Principal investigators: Moayyedi, Paul; Calliou, Skylin N; Daley, Kimberlee; De Nino, Alysia; Desjarlais, Rhonda; Marsiglio, Megan L; Munro, Sandra; Baumgart, Daniel C; Bercik, Premysl; Bernstein, Charles N; de Souza, Russell J; Dieleman, Levinus A; D'Silva, Adrijana; Ghia, Jean-Eric; Graff, Lesley A; Jones, Meaghan J; Kao, Dina H; Lavis, John N; Leontiadis, Grigorios; Libertucci, Josie; Ma, Christopher; Madsen, Karen L; Marshall, Deborah A; Narula, Neeraj; Nguyen, Geoffrey C; Otley, Anthony R; Panaccione, Remo; Pena-Sanchez, Juan-Nicolas; Presseau, Justin; Ruzycki, Shannon M; Surette, Michael G; Swain, Mark G; Tandon, Puneeta; Taylor, Valerie Hannah; Tremblay, Melissa; Tripp, Dean A; Vanner, Stephen J; Verdu, Elena F; Walters, Thomas D; Wine, Eytan

Keywords: Anxiety; Depression; Diet; Implementation Science; Inflammatory Bowel Disease; Irritable Bowel Syndrome; Knowledge Mobilization; Microbiome; Patient Orientated Research

$3,745,000

Serological Testing to Outline Protocols for COVID19 in Inflammatory Bowel Disease: STOP COVID-19 in IBD

Co-investigatorCIHR2020Op Grant: COVID-19 Rapid Research FO - Social Policy and Public Health Responses

Principal investigators: Kaplan, Gilaad G; Mawani, Mina; Morrin, Louise; Benchimol, Eric I; Munro, Sandra; Tipples, Graham A

Keywords: Covid-19; Crohn'S Disease; Immunocompromised; Inflammatory Bowel Disease; Knowledge Translation; Modeling; Sars-Cov-2; Serology; Seropositive; Ulcerative Colitis

$636,750

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Christopher Ma

Research

Latest papers

Latest funding

COMPARATIVE REAL-WORLD EFFECTIVENESS OF BIOLOGIC THERAPIES FOR PREVENTING POSTOPERATIVE ENDOSCOPIC RECURRENCE OF CROHN'S DISEASE.

Effectiveness of Risankizumab After Ustekinumab Failure in Crohn's Disease: A Multicenter Retrospective Cohort Study.

Antibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies.

Recommendations for the Evaluation and Management of Inflammatory Bowel Disease With Irritable Bowel Syndrome-Like Symptoms: A Joint Rome Foundation and International Organization for the Study of IBD (IOIBD) Consensus.

Inflammatory and Immune Pathways Driving Tumor Necrosis Factor Inhibitor Resistance in Ulcerative Colitis.

The Incidence of Esophageal Food Impactions and Risk Factors for Recurrence in a Large, Community-Based Health Care System in Northern California.

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.

Temporal trends in depression-related hospitalizations and suicide among patients with inflammatory bowel disease.

Comparative Outcomes After Index Myocardial Infarction in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Incidence and prevalence of immune-mediated extraintestinal manifestations in pediatric inflammatory bowel disease: a systematic review and meta-analysis.

Steatotic Liver Disease, Fibrosis and Inflammatory Bowel Disease: Uncovering the Triple Threat

Inflammatory Bowel Disease in 2035: A National Study of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC)

VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients with Cancer: A Randomized, Double-Blinded, Placebo-Controlled Trial

Managing the Burden of Inflammatory Bowel Disease over the Next Decade: A National Study of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC)

PATHFINDER: A Pragmatic, Active Comparator, Parallel-Group, Randomized Trial to Evaluate the Optimal First-Line Treatment Strategy for Moderate to Severely Active Ileal Crohn's Disease

IMAGINE (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects) SPOR Chronic Disease Network - Knowledge Mobilization & Implementation Science Phase 2

Serological Testing to Outline Protocols for COVID19 in Inflammatory Bowel Disease: STOP COVID-19 in IBD

Frequent collaborators

Vipul Jairath

Remo Panaccione

Neeraj Narula

Guangyong Zou

Cathy Lu

Yuhong Yuan

Talat Bessissow

Nauzer Forbes

John Kenneth Marshall

Yasmin Nasser

Abdel-Aziz Shaheen

Farhad Peerani

Humberto Jijon

Waqqas Afif

Sasha Bernatsky

Sasha Bernatsky

Brian Feagan

Harminder Singh

Jayna Holroyd-Leduc

Jayna Holroyd-Leduc

Sanjay Murthy

Michael Laffin

Harminder Singh

Graham Tipples

Hisham Akhtar

Karen Kroeker

Anton Skaro

Alan Barkun

Amanda Ricciuto

Dina El Demellawy

Douglas Quan

Daniel von Renteln